{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:15:10Z","timestamp":1794557710114,"version":"4.9.1"},"reference-count":156,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T00:00:00Z","timestamp":1774137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shenzhen High-level Hospital Construction Fund","award":["25260G1002"],"award-info":[{"award-number":["25260G1002"]}]},{"name":"Shenzhen Medical Academy of Research and Translation","award":["No. D250403009"],"award-info":[{"award-number":["No. D250403009"]}]},{"DOI":"10.13039\/501100001809","name":"the National Nature Science Foundation of China","doi-asserted-by":"crossref","award":["Grant Numbers 32394014"],"award-info":[{"award-number":["Grant Numbers 32394014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project","award":["2025ZD01907900"],"award-info":[{"award-number":["2025ZD01907900"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-026-04978-7","type":"journal-article","created":{"date-parts":[[2026,3,22]],"date-time":"2026-03-22T05:35:42Z","timestamp":1774157742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["From bench to bedside: advances in cell therapy for tuberculosis treatment"],"prefix":"10.1186","volume":"17","author":[{"given":"Li","family":"Chunxiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Junsheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Xuerong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Xiaomin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Shuihua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,22]]},"reference":[{"issue":"11","key":"4978_CR1","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","volume":"20","author":"VA Dartois","year":"2022","unstructured":"Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol. 2022;20(11):685\u2013701.","journal-title":"Nat Rev Microbiol"},{"key":"4978_CR2","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.ijid.2022.03.011","volume":"124","author":"J Chakaya","year":"2022","unstructured":"Chakaya J, Petersen E, Nantanda R, Mungai BN, Migliori GB, Amanullah F, et al. The WHO Global Tuberculosis 2021 Report\u2014not so good news and turning the tide back to end TB. Int J Infect Dis. 2022;124:S26-9.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"4978_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IM9.0000000000000169","volume":"7","author":"KF Bi","year":"2025","unstructured":"Bi KF, Zhao YL, Lu SH, Xu KJ, Zhang Y. Comments on the WHO global tuberculosis report 2024: progress, challenges and innovations for achieving end TB strategy by 2035. Infect Microbe Dis. 2025;7(1):1\u20134.","journal-title":"Infect Microbe Dis"},{"key":"4978_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jctube.2025.100522","author":"F Estaji","year":"2025","unstructured":"Estaji F, Kamali A, Keikha M. Strengthening the global response to tuberculosis: insights from the 2024 WHO global TB report. J Clin Tuberc Other Mycobact Dis. 2025. https:\/\/doi.org\/10.1016\/j.jctube.2025.100522.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"10","key":"4978_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41579-024-01025-1","volume":"22","author":"M Farhat","year":"2024","unstructured":"Farhat M, Cox H, Ghanem M, Denkinger CM, Rodrigues C, Abd El Aziz MS, et al. Drug-resistant tuberculosis: a persistent global health concern. Nat Rev Microbiol. 2024;22(10):617\u201335.","journal-title":"Nat Rev Microbiol"},{"issue":"9","key":"4978_CR6","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1136\/thoraxjnl-2018-211616","volume":"74","author":"KA Cohen","year":"2019","unstructured":"Cohen KA, Manson AL, Abeel T, Desjardins CA, Chapman SB, Hoffner S, et al. Extensive global movement of multidrug-resistant M. tuberculosis strains revealed by whole-genome analysis. Thorax. 2019;74(9):882\u20139.","journal-title":"Thorax"},{"issue":"3","key":"4978_CR7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jinf.2023.06.014","volume":"87","author":"OS Pedersen","year":"2023","unstructured":"Pedersen OS, Holmgaard FB, Mikkelsen MKD, Lange C, Sotgiu G, Lillebaek T, et al. Global treatment outcomes of extensively drug-resistant tuberculosis in adults: a systematic review and meta-analysis. J Infect. 2023;87(3):177\u201389.","journal-title":"J Infect"},{"key":"4978_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00504-2","author":"K Dheda","year":"2024","unstructured":"Dheda K, Mirzayev F, Cirillo DM, Udwadia Z, Dooley KE, Chang K-C, et al. multidrug-resistant tuberculosis. Nat Rev Dis Primers. 2024. https:\/\/doi.org\/10.1038\/s41572-024-00504-2.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"4978_CR9","doi-asserted-by":"publisher","first-page":"E47","DOI":"10.1016\/S1473-3099(16)00078-5","volume":"16","author":"A Zumla","year":"2016","unstructured":"Zumla A, Rao M, Wallis RS, Kaufmann SHE, Rustomjee R, Mwaba P, et al. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect Dis. 2016;16(4):E47\u201363.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"4978_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41551-018-0246-6","volume":"2","author":"A Aijaz","year":"2018","unstructured":"Aijaz A, Li M, Smith D, Khong D, LeBlon C, Fenton OS, et al. Biomanufacturing for clinically advanced cell therapies. Nat Biomed Eng. 2018;2(6):362\u201376.","journal-title":"Nat Biomed Eng"},{"issue":"10","key":"4978_CR11","first-page":"669","volume":"16","author":"A Mullard","year":"2017","unstructured":"Mullard A. FDA approves first CAR T therapy. Nat Rev Drug Discov. 2017;16(10):669.","journal-title":"Nat Rev Drug Discov"},{"key":"4978_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03782-5","author":"E Jiang","year":"2024","unstructured":"Jiang E, Qian K, Wang L, Yang DL, Shao YL, Hu LD, et al. Efficacy and safety of human umbilical cord-derived mesenchymal stem cells versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease: a multicentre, randomized, double-blind, phase 2 trial. BMC Med. 2024. https:\/\/doi.org\/10.1186\/s12916-024-03782-5.","journal-title":"BMC Med"},{"key":"4978_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00932-0","author":"YY Han","year":"2022","unstructured":"Han YY, Yang JX, Fang JK, Zhou YP, Candi E, Wang JH, et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduct Target Ther. 2022. https:\/\/doi.org\/10.1038\/s41392-022-00932-0.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"4978_CR14","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41423-023-00998-y","volume":"20","author":"PS Li","year":"2023","unstructured":"Li PS, Ou QM, Shi ST, Shao CS. Immunomodulatory properties of mesenchymal stem cells\/dental stem cells and their therapeutic applications. Cell Mol Immunol. 2023;20(6):558\u201369.","journal-title":"Cell Mol Immunol"},{"key":"4978_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-02716-3","author":"YT Chen","year":"2022","unstructured":"Chen YT, Huang HC, Li GX, Yu JY, Fang FC, Qiu W. Dental-derived mesenchymal stem cell sheets: a prospective tissue engineering for regenerative medicine. Stem Cell Res Ther. 2022. https:\/\/doi.org\/10.1186\/s13287-022-02716-3.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4978_CR16","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3892\/ijmm.2015.2413","volume":"37","author":"JS Heo","year":"2016","unstructured":"Heo JS, Choi Y, Kim HS, Kim HO. Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue. Int J Mol Med. 2016;37(1):115\u201325.","journal-title":"Int J Mol Med"},{"key":"4978_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020481","author":"A Mucientes","year":"2021","unstructured":"Mucientes A, Herranz E, Moro E, Gonz\u00e1lez-Corch\u00f3n A, Pe\u00f1a-Soria MJ, Abasolo L, et al. Influence of mesenchymal stem cell sources on their regenerative capacities on different surfaces. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10020481.","journal-title":"Cells"},{"issue":"17","key":"4978_CR18","doi-asserted-by":"publisher","first-page":"8558","DOI":"10.1111\/jcmm.16817","volume":"25","author":"YJ Xie","year":"2021","unstructured":"Xie YJ, Chen F, Jia L, Chen R, Zhang VW, Zhong XQ, Wang D. Mesenchymal stem cells from different sources show distinct therapeutic effects in hyperoxia-induced bronchopulmonary dysplasia in rats. J Cell Mol Med. 2021;25(17):8558\u201366.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"4978_CR19","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s10787-024-01468-1","volume":"32","author":"LH Shi","year":"2024","unstructured":"Shi LH, Chen LL, Gao XZ, Sun XF, Jin GY, Yang YH, et al. Comparison of different sources of mesenchymal stem cells: focus on inflammatory bowel disease. Inflammopharmacology. 2024;32(3):1721\u201342.","journal-title":"Inflammopharmacology"},{"key":"4978_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01208-w","author":"TX Lan","year":"2021","unstructured":"Lan TX, Luo M, Wei XW. Mesenchymal stem\/stromal cells in cancer therapy. J Hematol Oncol. 2021. https:\/\/doi.org\/10.1186\/s13045-021-01208-w.","journal-title":"J Hematol Oncol"},{"key":"4978_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-02782-7","author":"SA Jasim","year":"2022","unstructured":"Jasim SA, Yumashev AV, Abdelbasset WK, Margiana R, Markov A, Suksatan W, et al. Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases. Stem Cell Res Ther. 2022. https:\/\/doi.org\/10.1186\/s13287-022-02782-7.","journal-title":"Stem Cell Res Ther"},{"key":"4978_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114817","author":"YH Pan","year":"2023","unstructured":"Pan YH, Wu WP, Jiang XX, Liu YH. Mesenchymal stem cell-derived exosomes in cardiovascular and cerebrovascular diseases: from mechanisms to therapy. Biomed Pharmacother. 2023. https:\/\/doi.org\/10.1016\/j.biopha.2023.114817.","journal-title":"Biomed Pharmacother"},{"key":"4978_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1469696","author":"A Hazrati","year":"2024","unstructured":"Hazrati A, Mirarefin SMJ, Malekpour K, Rahimi A, Khosrojerdi A, Rasouli A, et al. Mesenchymal stem cell application in pulmonary disease treatment with emphasis on their interaction with lung-resident immune cells. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1469696.","journal-title":"Front Immunol"},{"issue":"13","key":"4978_CR24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1089\/scd.2020.0208","volume":"30","author":"J Liu","year":"2021","unstructured":"Liu J, Peng DY, You JY, Zhou O, Qiu HJ, Hao C, et al. Type 2 alveolar epithelial cells differentiated from human umbilical cord mesenchymal stem cells alleviate mouse pulmonary fibrosis through \u03b2-catenin-regulated cell apoptosis. Stem Cells Dev. 2021;30(13):660\u201370.","journal-title":"Stem Cells Dev"},{"issue":"3","key":"4978_CR25","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1164\/rccm.201410-1765OC","volume":"192","author":"A Monsel","year":"2015","unstructured":"Monsel A, Zhu YG, Gennai S, Hao Q, Hu SL, Rouby JJ, et al. Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice. Am J Resp Crit Care. 2015;192(3):324\u201336.","journal-title":"Am J Resp Crit Care"},{"issue":"6","key":"4978_CR26","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/thoraxjnl-2011-201176","volume":"67","author":"N Gupta","year":"2012","unstructured":"Gupta N, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan XP, Serikov V, et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine pneumonia. Thorax. 2012;67(6):533\u20139.","journal-title":"Thorax"},{"issue":"1","key":"4978_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/jpi.12140","volume":"57","author":"HH Chen","year":"2014","unstructured":"Chen HH, Lin KC, Wallace CG, Chen YT, Yang CC, Leu S, et al. Additional benefit of combined therapy with melatonin and apoptotic adipose-derived mesenchymal stem cell against sepsis-induced kidney injury. J Pineal Res. 2014;57(1):16\u201332.","journal-title":"J Pineal Res"},{"key":"4978_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.166014","author":"M Jeyaraman","year":"2021","unstructured":"Jeyaraman M, John A, Koshy S, Ranjan R, Anudeep TC, Jain R, et al. Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19. Biochim et Biophys Acta (BBA). 2021. https:\/\/doi.org\/10.1016\/j.bbadis.2020.166014.","journal-title":"Biochim et Biophys Acta (BBA)"},{"key":"4978_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123062","author":"AN Muraviov","year":"2022","unstructured":"Muraviov AN, Vinogradova TI, Remezova AN, Ariel BM, Gorelova AA, Orlova NV, et al. The use of mesenchymal stem cells in the complex treatment of kidney tuberculosis (experimental study). Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10123062.","journal-title":"Biomedicines"},{"key":"4978_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2024.102593","author":"QW Yang","year":"2025","unstructured":"Yang QW, Zhou YQ, Farooq W, Liu QM, Duan JH, Xing L, et al. The immunomodulatory effects of mesenchymal stem cells on THP-1-derived macrophages against mycobacterium tuberculosis H37Ra infection. Tuberculosis. 2025. https:\/\/doi.org\/10.1016\/j.tube.2024.102593.","journal-title":"Tuberculosis"},{"key":"4978_CR31","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.reth.2018.09.001","volume":"9","author":"L Danjuma","year":"2018","unstructured":"Danjuma L, Mok PL, Higuchi A, Hamat RA, Teh SW, Koh AEH, et al. Modulatory and regenerative potential of transplanted bone marrow-derived mesenchymal stem cells on rifampicin-induced kidney toxicity. Regen Ther. 2018;9:100\u201310.","journal-title":"Regen Ther"},{"key":"4978_CR32","doi-asserted-by":"crossref","unstructured":"Bonfield TL, Auster L, Ragavapuram V, Fletcher D, Sutton M, Somoza R, et al. Mesenchymal stem cell therapy and chronic non-tuberculous mycobacterium infection. Am J Resp Crit Care. 2019;199.","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A2657"},{"key":"4978_CR33","doi-asserted-by":"crossref","unstructured":"Skrahin A, Ahmed R, Ferrara G, Rane L, Poiret T, Isaikina Y et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis (M\/XDR-TB): an open-label phase 1 safety trial. Eur Respir J. 2014;44.","DOI":"10.1183\/13993003\/erj.44.Suppl_58.1898"},{"key":"4978_CR34","unstructured":"Erokhin VV, Vasil\u2019eva IA, Konopliannikov AG, Chukanov VI, Tsyb AF, Bagdasarian TR, et al. Systemic transplantation of autologous mesenchymal stem cells of the bone marrow in the treatment of patients with multidrug-resistant pulmonary tuberculosis. Probl Tuberk Bolezn Legk. 2008;(10):3\u20136."},{"key":"4978_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jctube.2016.05.003","volume":"4","author":"A Skrahin","year":"2016","unstructured":"Skrahin A, Jenkins HE, Hurevich H, Solodovnikova V, Isaikina Y, Klimuk D, et al. Effectiveness of a novel cellular therapy to treat multidrug-resistant tuberculosis. J Clin Tuberc Other Mycobact Dis. 2016;4:21\u20137.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"7","key":"4978_CR36","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.ajpath.2015.03.028","volume":"185","author":"J Garhyan","year":"2015","unstructured":"Garhyan J, Bhuyan S, Pulu I, Kalita D, Das B, Bhatnagar R. Preclinical and clinical evidence of persistence in the hypoxic niche of bone marrow mesenchymal stem cells after therapy. Am J Pathol. 2015;185(7):1924\u201334.","journal-title":"Am J Pathol"},{"issue":"5","key":"4978_CR37","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/infdis\/jiy579","volume":"219","author":"J Mayito","year":"2019","unstructured":"Mayito J, Andia I, Belay M, Jolliffe DA, Kateete DP, Reece ST, et al. Anatomic and cellular niches for mycobacterium tuberculosis in latent tuberculosis infection. J Infect Dis. 2019;219(5):685\u201394.","journal-title":"J Infect Dis"},{"key":"4978_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16877-3","author":"N Jain","year":"2020","unstructured":"Jain N, Kalam H, Singh L, Sharma V, Kedia S, Das P, et al. Mesenchymal stem cells offer a drug-tolerant and immune-privileged niche to mycobacterium tuberculosis. Nat Commun. 2020. https:\/\/doi.org\/10.1038\/s41467-020-16877-3.","journal-title":"Nat Commun"},{"key":"4978_CR39","doi-asserted-by":"crossref","unstructured":"Aqdas M, Singh S, Amir M, Maurya SK, Pahari S, Agrewala JN. Cumulative signaling through NOD-2 and TLR-4 eliminates the concealed inside the mesenchymal stem cells. Front Cell Infect Mi. 2021;11.","DOI":"10.3389\/fcimb.2021.669168"},{"key":"4978_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.756495","author":"J Liang","year":"2021","unstructured":"Liang J, Fu L, Li M, Chen YY, Wang Y, Lin Y, et al. Allogeneic V\u03b39V\u03b42 T-cell therapy promotes pulmonary lesion repair: an open-label, single-arm pilot study in patients with multidrug-resistant tuberculosis. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.756495.","journal-title":"Front Immunol"},{"issue":"1","key":"4978_CR41","first-page":"97","volume":"34","author":"JC Xu","year":"2017","unstructured":"Xu JC, Chen XN, Ye ZJ, Wu MY, Shi CL, Tang PJ, et al. New attempt in tuberculosis treatment: autologous cytokine-induced killer after chemotherapy treatment failure in a case of multi-drug resistant tuberculosis (M.tb). Sarcoidosis Vasc Dif. 2017;34(1):97\u20139.","journal-title":"Sarcoidosis Vasc Dif"},{"issue":"10","key":"4978_CR42","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2217\/imt-2017-0192","volume":"10","author":"P Xu","year":"2018","unstructured":"Xu P, Pang Y, Xu JC, Chen H, Tang PJ, Wu MY. Cytokine-induced killer cell therapy as a promising adjunctive immunotherapy for multidrug-resistant pulmonary TB: a case report. Immunotherapy-Uk. 2018;10(10):827\u201330.","journal-title":"Immunotherapy-Uk"},{"key":"4978_CR43","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2943113","author":"PJ Tang","year":"2022","unstructured":"Tang PJ, Chen XN, Xu JC, Hu YL, Ye ZJ, Wang XF, et al. Autologous cytokine-induced killer cell immunotherapy enhances chemotherapy efficacy against multidrug-resistant tuberculosis. J Immunol Res. 2022. https:\/\/doi.org\/10.1155\/2022\/2943113.","journal-title":"J Immunol Res"},{"key":"4978_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612594","author":"B Chouaib","year":"2023","unstructured":"Chouaib B, Haack-Sorensen M, Chaubron F, Cuisinier F, Collart-Dutilleul PY. Towards the standardization of mesenchymal stem cell secretome-derived product manufacturing for tissue regeneration. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241612594.","journal-title":"Int J Mol Sci"},{"key":"4978_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18091852","author":"FJ Vizoso","year":"2017","unstructured":"Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci. 2017. https:\/\/doi.org\/10.3390\/ijms18091852.","journal-title":"Int J Mol Sci"},{"key":"4978_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-023-03264-0","author":"M Ghasemi","year":"2023","unstructured":"Ghasemi M, Roshandel E, Mohammadian M, Farhadihosseinabadi B, Akbarzadehlaleh P, Shamsasenjan K. Mesenchymal stromal cell-derived secretome-based therapy for neurodegenerative diseases: overview of clinical trials. Stem Cell Res Ther. 2023. https:\/\/doi.org\/10.1186\/s13287-023-03264-0.","journal-title":"Stem Cell Res Ther"},{"key":"4978_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cells12212565","author":"B Mendes-Pinheiro","year":"2023","unstructured":"Mendes-Pinheiro B, Campos J, Marote A, Soares-Cunha C, Nickels SL, Monzel AS, et al. Treating Parkinson\u2019s disease with human bone marrow mesenchymal stem cell secretome: a translational investigation using human brain organoids and different routes of in vivo administration. Cells. 2023. https:\/\/doi.org\/10.3390\/cells12212565.","journal-title":"Cells"},{"key":"4978_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-019-0242-9","author":"TG Shah","year":"2019","unstructured":"Shah TG, Predescu D, Predescu S. Mesenchymal stem cells-derived extracellular vesicles in acute respiratory distress syndrome: a review of current literature and potential future treatment options. Clin Transl Med. 2019. https:\/\/doi.org\/10.1186\/s40169-019-0242-9.","journal-title":"Clin Transl Med"},{"key":"4978_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-019-1352-4","author":"KS Park","year":"2019","unstructured":"Park KS, Svennerholm K, Shelke G, Bandeira E, L\u00e4sser C, Jang SC, et al. Mesenchymal stromal cell-derived nanovesicles ameliorate bacterial outer membrane vesicle-induced sepsis via IL-10. Stem Cell Res Ther. 2019. https:\/\/doi.org\/10.1186\/s13287-019-1352-4.","journal-title":"Stem Cell Res Ther"},{"key":"4978_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118658","author":"MY Yao","year":"2021","unstructured":"Yao MY, Cui B, Zhang WH, Ma WT, Zhao GF, Xing LH. Exosomal miR-21 secreted by IL-1\u03b2-primed-mesenchymal stem cells induces macrophage M2 polarization and ameliorates sepsis. Life Sci. 2021. https:\/\/doi.org\/10.1016\/j.lfs.2020.118658.","journal-title":"Life Sci"},{"issue":"5","key":"4978_CR51","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/stem.2564","volume":"35","author":"YX Song","year":"2017","unstructured":"Song YX, Dou H, Li XJ, Zhao XY, Li Y, Liu D, et al. Exosomal miR-146a contributes to the enhanced therapeutic efficacy of interleukin-1-primed mesenchymal stem cells against sepsis. Stem Cells. 2017;35(5):1208\u201321.","journal-title":"Stem Cells"},{"key":"4978_CR52","doi-asserted-by":"crossref","unstructured":"Yudintceva N, Bobkov D, Sulatsky M, Mikhailova N, Oganesyan E, Vinogradova T et al. Mesenchymal stem cells-derived extracellular vesicles for therapeutics of renal tuberculosis. Sci Rep-Uk. 2024;14(1).","DOI":"10.1038\/s41598-024-54992-z"},{"key":"4978_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2022.105292","author":"KY Yan","year":"2022","unstructured":"Yan KY, Xu GY, Li Z. MicroRNA-20b carried by mesenchymal stem cell-derived extracellular vesicles protects alveolar epithelial type II cells from mycobacterium tuberculosis infection in vitro. Infect Genet Evol. 2022. https:\/\/doi.org\/10.1016\/j.meegid.2022.105292.","journal-title":"Infect Genet Evol"},{"issue":"4","key":"4978_CR54","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1097\/ID.0000000000000618","volume":"26","author":"W Katagiri","year":"2017","unstructured":"Katagiri W, Watanabe J, Toyama N, Osugi M, Sakaguchi K, Hibi H. Clinical study of bone regeneration by conditioned medium from mesenchymal stem cells after maxillary sinus floor elevation. Implant Dent. 2017;26(4):607\u201312.","journal-title":"Implant Dent"},{"issue":"3","key":"4978_CR55","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5021\/ad.21.287","volume":"35","author":"HJ Ahn","year":"2023","unstructured":"Ahn HJ, Kim YJ, Myeong S, Huh G, Kim WS. Clinical evaluation of conditioned media of human umbilical cord blood mesenchymal stem cells for improvement of symptoms of sensitive skin: prospective, single blinded, split-face study. Ann Dermatol. 2023;35(3):165\u201372.","journal-title":"Ann Dermatol"},{"issue":"4","key":"4978_CR56","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/term.2806","volume":"13","author":"TNA Gunawardena","year":"2019","unstructured":"Gunawardena TNA, Rahman MT, Abdullah BJJ, Abu Kasim NH. Conditioned media derived from mesenchymal stem cell cultures: the next generation for regenerative medicine. J Tissue Eng Regen Med. 2019;13(4):569\u201386.","journal-title":"J Tissue Eng Regen Med"},{"key":"4978_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13005-016-0101-5","author":"W Katagiri","year":"2016","unstructured":"Katagiri W, Osugi M, Kawai T, Hibi H. First-in-human study and clinical case reports of the alveolar bone regeneration with the secretome from human mesenchymal stem cells. Head Face Med. 2016. https:\/\/doi.org\/10.1186\/s13005-016-0101-5.","journal-title":"Head Face Med"},{"issue":"12","key":"4978_CR58","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1002\/stem.544","volume":"28","author":"A Krasnodembskaya","year":"2010","unstructured":"Krasnodembskaya A, Song YL, Fang XH, Gupta N, Serikov V, Lee JW, Matthay MA. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells. 2010;28(12):2229\u201338.","journal-title":"Stem Cells"},{"key":"4978_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-021-02622-0","author":"M Bahroudi","year":"2021","unstructured":"Bahroudi M, Bakhshi B, Soudi S, Najar-Peerayeh S. Immunomodulatory effects of mesenchymal stem cell-conditioned media on lipopolysaccharide of vibrio cholerae as a vaccine candidate. Stem Cell Res Ther. 2021. https:\/\/doi.org\/10.1186\/s13287-021-02622-0.","journal-title":"Stem Cell Res Ther"},{"key":"4978_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121465","author":"A Chenari","year":"2023","unstructured":"Chenari A, Hazrati A, Hosseini AZ, Motiee M, Soudi S. The effect of mesenchymal stem cell-derived supernatant nasal administration on lung inflammation and immune response in BCG-vaccinated BALB\/c mice. Life Sci. 2023. https:\/\/doi.org\/10.1016\/j.lfs.2023.121465.","journal-title":"Life Sci"},{"key":"4978_CR61","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-02808-z","author":"A Dogra","year":"2025","unstructured":"Dogra A, Yadav RK, Singh H, Datt V. Emerging frontiers in adoptive cell therapies: innovations, challenges, and future perspectives. Med Oncol. 2025. https:\/\/doi.org\/10.1007\/s12032-025-02808-z.","journal-title":"Med Oncol"},{"issue":"1","key":"4978_CR62","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.immuni.2014.05.018","volume":"41","author":"P Graef","year":"2014","unstructured":"Graef P, Buchholz VR, Stemberger C, Flossdorf M, Henkel L, Schiemann M, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8 central memory T cells. Immunity. 2014;41(1):116\u201326.","journal-title":"Immunity"},{"key":"4978_CR63","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","volume":"22","author":"F Sallusto","year":"2004","unstructured":"Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745\u201363.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"4978_CR64","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/ni.2038","volume":"12","author":"M Pepper","year":"2011","unstructured":"Pepper M, Jenkins MK. Origins of CD4 effector and central memory T cells. Nat Immunol. 2011;12(6):467\u201371.","journal-title":"Nat Immunol"},{"issue":"6754","key":"4978_CR65","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/44385","volume":"401","author":"F Sallusto","year":"1999","unstructured":"Sallusto F, Lenig D, F\u00f6rster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708\u201312.","journal-title":"Nature"},{"issue":"5258","key":"4978_CR66","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1126\/science.272.5258.54","volume":"272","author":"R Ahmed","year":"1996","unstructured":"Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science. 1996;272(5258):54\u201360.","journal-title":"Science"},{"key":"4978_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.781029","author":"JQ Cai","year":"2021","unstructured":"Cai JQ, Zhao JJ, Liu DF, Xie HF, Qi HL, Ma JF, et al. Efficacy and safety of central memory T cells combined with adjuvant therapy to prevent recurrence of hepatocellular carcinoma with microvascular invasion: a pilot study. Front Oncol. 2021. https:\/\/doi.org\/10.3389\/fonc.2021.781029.","journal-title":"Front Oncol"},{"key":"4978_CR68","doi-asserted-by":"publisher","first-page":"S674","DOI":"10.1097\/01.tp.0000543615.33191.20","volume":"102","author":"J Zhang","year":"2018","unstructured":"Zhang J, Ma XQ, Yang CJ, Fang Q, Dong Q, Wang W. A novel generative mycobacterium tuberculosis-specific T cells method for adoptive cellular therapy. Transplantation. 2018;102:S674-S.","journal-title":"Transplantation"},{"key":"4978_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01041","author":"Z Xiang","year":"2017","unstructured":"Xiang Z, Tu WW. Dual face of V\u03b39V\u03b42-T cells in tumor immunology: anti-versus pro-tumoral activities. Front Immunol. 2017. https:\/\/doi.org\/10.3389\/fimmu.2017.01041.","journal-title":"Front Immunol"},{"issue":"6","key":"4978_CR70","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.4049\/jimmunol.1900592","volume":"203","author":"M Papadopoulou","year":"2019","unstructured":"Papadopoulou M, Tieppo P, McGovern N, Gosselin F, Chan JKY, Goetgeluk G, et al. TCR sequencing reveals the distinct development of fetal and adult human V\u03b39V\u03b42 T cells. J Immunol. 2019;203(6):1468\u201379.","journal-title":"J Immunol"},{"key":"4978_CR71","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00800","author":"T Hoeres","year":"2018","unstructured":"Hoeres T, Smetak M, Pretscher D, Wilhelm M. Improving the efficiency of V\u03b39V\u03b42 T cell immunotherapy in cancer. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.00800.","journal-title":"Front Immunol"},{"key":"4978_CR72","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2019.1649971","author":"N Joalland","year":"2019","unstructured":"Joalland N, Lafrance L, Oullier T, Marionneau-Lambot S, Loussouarn D, Jurry U, et al. Combined chemotherapy and allogeneic human V\u03b39V\u03b42 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells. Oncoimmunology. 2019. https:\/\/doi.org\/10.1080\/2162402x.2019.1649971.","journal-title":"Oncoimmunology"},{"issue":"23","key":"4978_CR73","doi-asserted-by":"publisher","first-page":"7218","DOI":"10.1158\/1078-0432.CCR-19-0375","volume":"25","author":"C Chauvin","year":"2019","unstructured":"Chauvin C, Joalland N, Perroteau J, Jarry U, Lafrance L, Willem C, et al. NKG2D controls natural reactivity of V\u03b39V\u03b42 T lymphocytes against mesenchymal glioblastoma cells. Clin Cancer Res. 2019;25(23):7218\u201328.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4978_CR74","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.coi.2006.07.002","volume":"18","author":"M Bonneville","year":"2006","unstructured":"Bonneville M, Scotet E. Human V\u03b39V\u03b42 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol. 2006;18(5):539\u201346.","journal-title":"Curr Opin Immunol"},{"issue":"2","key":"4978_CR75","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/CJI.0b013e318245bb1e","volume":"35","author":"V Kunzmann","year":"2012","unstructured":"Kunzmann V, Smetak M, Kimmel B, Weigang-Koehler K, Goebeler M, Birkmann J, et al. Tumor-promoting versus tumor-antagonizing roles of \u03b3\u03b4 T cells in cancer immunotherapy: results from a prospective phase I\/II trial. J Immunother. 2012;35(2):205\u201313.","journal-title":"J Immunother"},{"issue":"7","key":"4978_CR76","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/BF03403540","volume":"5","author":"F Poccia","year":"1999","unstructured":"Poccia F, Malkovsky M, Pollak A, Colizzi V, Sireci G, Salerno A, et al. In vivo \u03b3\u03b4 T cell priming to mycobacterial antigens by primary mycobacterium tuberculosis infection and exposure to nonpeptidic ligands. Mol Med. 1999;5(7):471\u20136.","journal-title":"Mol Med"},{"issue":"1","key":"4978_CR77","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/imr.12927","volume":"298","author":"L Shen","year":"2020","unstructured":"Shen L, Huang D, Qaqish A, Frencher J, Yang R, Shen HB, Chen ZW. Fast-acting \u03b3\u03b4 T-cell subpopulation and protective immunity against infections. Immunol Rev. 2020;298(1):254\u201363.","journal-title":"Immunol Rev"},{"issue":"3","key":"4978_CR78","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1128\/IAI.72.3.1504-1511.2004","volume":"72","author":"J Lee","year":"2004","unstructured":"Lee J, Choi KW, Olin MR, Cho SN, Molitor TW. \u03b3\u03b4 T cells in immunity induced by bacillus Calmette-Guerin vaccination. Infect Immun. 2004;72(3):1504\u201311.","journal-title":"Infect Immun"},{"issue":"5","key":"4978_CR79","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.4049\/jimmunol.179.5.3057","volume":"179","author":"A Martino","year":"2007","unstructured":"Martino A, Casetti R, Sacchi A, Poccia F. Central memory V\u03b39V\u03b42 T lymphocytes primed and expanded by bacillus Calmette-Guerin-infected dendritic cells kill mycobacterial-infected monocytes. J Immunol. 2007;179(5):3057\u201364.","journal-title":"J Immunol"},{"issue":"3","key":"4978_CR80","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.4049\/jimmunol.168.3.1484","volume":"168","author":"C Gioia","year":"2002","unstructured":"Gioia C, Agrati C, Casetti R, Cairo C, Borsellino G, Battistini L, et al. Lack of CD27CD45RA-V\u03b39V\u03b42T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. J Immunol. 2002;168(3):1484\u20139.","journal-title":"J Immunol"},{"issue":"2","key":"4978_CR81","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cellimm.2013.05.001","volume":"282","author":"S El Daker","year":"2013","unstructured":"El Daker S, Sacchi A, Montesano C, Altieri AM, Galluccio G, Colizzi V, et al. An abnormal phenotype of lung V\u03b39V\u03b42 T cells impairs their responsiveness in tuberculosis patients. Cell Immunol. 2013;282(2):106\u201312.","journal-title":"Cell Immunol"},{"key":"4978_CR82","doi-asserted-by":"crossref","unstructured":"Liu SY, Xiao GH, Liang WX, Zhang S, Liang J, Pan T et al. V\u03b39V\u03b42 T cells expanded with vitamin C combined with HMBPP inhibit intracellular Mycobacterium tuberculosis growth. Front Cell Infect Mi. 2025;15.","DOI":"10.3389\/fcimb.2025.1533277"},{"issue":"5343","key":"4978_CR83","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1126\/science.278.5343.1626","volume":"278","author":"T Kawano","year":"1997","unstructured":"Kawano T, Cui JQ, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-mediated activation of V(alpha)14 NKT cells by glycosylceramides. Science. 1997;278(5343):1626\u20139.","journal-title":"Science"},{"issue":"3","key":"4978_CR84","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.coi.2008.03.018","volume":"20","author":"JL Matsuda","year":"2008","unstructured":"Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L. CD1d-restricted iNKT cells, the \u2018Swiss-Army knife\u2019 of the immune system. Curr Opin Immunol. 2008;20(3):358\u201368.","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"4978_CR85","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1158\/2767-9764.CRC-23-0137","volume":"3","author":"J Wang","year":"2023","unstructured":"Wang J, Cheng XB, Jin YL, Xia BL, Qin R, Zhang W, et al. Safety and clinical response to combined immunotherapy with autologous iNKT cells and PD-1\u2009+\u2009CD8+ T cells in patients failing first-line chemotherapy in stage IV pancreatic cancer. Cancer Res Commun. 2023;3(6):991\u20131003.","journal-title":"Cancer Res Commun"},{"key":"4978_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44905-z","author":"TC Hammond","year":"2024","unstructured":"Hammond TC, Purbhoo MA, Kadel S, Ritz J, Nikiforow S, Daley H, et al. A phase 1\/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/s41467-024-44905-z.","journal-title":"Nat Commun"},{"issue":"2, Supplement","key":"4978_CR87","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jtct.2023.12.072","volume":"30","author":"CA Ramos","year":"2024","unstructured":"Ramos CA, Courtney AN, Lulla PD, Hill LC, Kamble RT, Carrum G, et al. Off-the-shelf CD19-specific CAR-NKT cells in patients with relapsed or refractory B-cell malignancies. Transplant Cell Ther. 2024;30(2, Supplement):S41\u20132.","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"4978_CR88","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s41591-024-02799-w","volume":"30","author":"A Heczey","year":"2024","unstructured":"Heczey A, Xu X, Courtney AN, Tian GW, Barragan GA, Guo LJ, et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results (29, pg 1379, 2023). Nat Med. 2024;30(4):1210.","journal-title":"Nat Med"},{"issue":"4","key":"4978_CR89","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4103\/ijmy.ijmy_141_19","volume":"8","author":"P Pandey","year":"2019","unstructured":"Pandey P, Bhatnagar AK, Mohan A, Sachdeva KS, Vajpayee M, Das BK, et al. Insights in tuberculosis immunology: role of NKT and T regulatory cells. Int J Mycobacteriol. 2019;8(4):333\u201340.","journal-title":"Int J Mycobacteriol"},{"issue":"11","key":"4978_CR90","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1128\/IAI.70.11.6302-6309.2002","volume":"70","author":"A Chackerian","year":"2002","unstructured":"Chackerian A, Alt J, Perera V, Behar SM. Activation of NKT cells protects mice from tuberculosis. Infect Immun. 2002;70(11):6302\u20139.","journal-title":"Infect Immun"},{"key":"4978_CR91","doi-asserted-by":"crossref","unstructured":"Sada-Ovalle I, Chiba A, Gonzales A, Brenner MB, Behar SM. Innate invariant NKT cells recognize-infected macrophages, produce interferon-\u03b3, and kill intracellular bacteria. Plos Pathog. 2008;4(12).","DOI":"10.1371\/journal.ppat.1000239"},{"issue":"6","key":"4978_CR92","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/sj.bjc.6690800","volume":"81","author":"IGH Schmidt-Wolf","year":"1999","unstructured":"Schmidt-Wolf IGH, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer. 1999;81(6):1009\u201316.","journal-title":"Br J Cancer"},{"key":"4978_CR93","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03605-1","author":"A Sharma","year":"2024","unstructured":"Sharma A, Ren XB, Rosato A, Sangiolo D, Wang ZB, Tettamanti S, et al. Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy. Cancer Immunol Immunother. 2024. https:\/\/doi.org\/10.1007\/s00262-023-03605-1.","journal-title":"Cancer Immunol Immunother"},{"key":"4978_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114732","author":"C-C Wu","year":"2023","unstructured":"Wu C-C, Pan M-R, Shih S-L, Shiau JP, Wu C-C, Chang S-J, et al. Combination of FAK inhibitor and cytokine-induced killer cell therapy: an alternative therapeutic strategy for patients with triple-negative breast cancer. Biomed Pharmacother. 2023. https:\/\/doi.org\/10.1016\/j.biopha.2023.114732.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"4978_CR95","doi-asserted-by":"publisher","first-page":"9291","DOI":"10.1002\/jcp.29827","volume":"235","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Schmidt-Wolf IGH. Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. J Cell Physiol. 2020;235(12):9291\u2013303.","journal-title":"J Cell Physiol"},{"key":"4978_CR96","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2119\/molmed.2017.00084","volume":"23","author":"G Mesiano","year":"2017","unstructured":"Mesiano G, Zini R, Montagner G, Bianchi N, Manfredini R, Chillemi A, et al. Analytic and dynamic secretory profile of patient-derived cytokine-induced killer cells. Mol Med. 2017;23:235\u201346.","journal-title":"Mol Med"},{"issue":"5156","key":"4978_CR97","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1126\/science.8146660","volume":"264","author":"P Constant","year":"1994","unstructured":"Constant P, Davodeau F, Peyrat MA, Poquet Y, Puzo G, Bonneville M, et al. Stimulation of human gamma-delta T-cells by nonpeptidic mycobacterial ligands. Science. 1994;264(5156):267\u201370.","journal-title":"Science"},{"issue":"12","key":"4978_CR98","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41577-020-0345-y","volume":"20","author":"DG Pellicci","year":"2020","unstructured":"Pellicci DG, Koay HF, Berzins SP. Thymic development of unconventional T cells: how NKT cells, MAIT cells and \u03b3\u03b4 T cells emerge. Nat Rev Immunol. 2020;20(12):756\u201370.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"4978_CR99","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.4049\/jimmunol.2100856","volume":"209","author":"M Dogan","year":"2022","unstructured":"Dogan M, Karhan E, Kozhaya L, Placek L, Chen X, Yigit M, Unutmaz D. Engineering human MAIT cells with chimeric antigen receptors for cancer immunotherapy. J Immunol. 2022;209(8):1523\u201331.","journal-title":"J Immunol"},{"key":"4978_CR100","doi-asserted-by":"crossref","unstructured":"Booth JS, Salerno-Goncalves R, Blanchard TG, Patil SA, Kader HA, Safta AM et al. Mucosal-associated invariant T cells in the human gastric mucosa and blood: role in infection. Front Immunol. 2015;6.","DOI":"10.3389\/fimmu.2015.00466"},{"key":"4978_CR101","doi-asserted-by":"crossref","unstructured":"Smith DJ, Hill GR, Bell SC, Reid DW. Reduced mucosal associated invariant T-cells are associated with increased disease severity and infection in cystic fibrosis. PLoS ONE. 2014;9(10).","DOI":"10.1371\/journal.pone.0109891"},{"issue":"5","key":"4978_CR102","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.molimm.2010.12.002","volume":"48","author":"P Georgel","year":"2011","unstructured":"Georgel P, Radosavljevic M, Macquin C, Bahram S. The non-conventional MHC class I MR1 molecule controls infection by Klebsiella pneumoniae in mice. Mol Immunol. 2011;48(5):769\u201375.","journal-title":"Mol Immunol"},{"key":"4978_CR103","doi-asserted-by":"crossref","unstructured":"Dey RJ, Dey B, Harriff M, Canfield ET, Lewinsohn DM, Bishai WR. Augmentation of the riboflavin-biosynthetic pathway enhances mucosa-associated invariant T (MAIT) cell activation and diminishes virulence. Mbio. 2022;13(1).","DOI":"10.1128\/mbio.03865-21"},{"issue":"1","key":"4978_CR104","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41385-020-0332-4","volume":"14","author":"S Sakai","year":"2021","unstructured":"Sakai S, Kauffman KD, Oh S, Nelson CE, Barry CE, Barber DL. MAIT cell-directed therapy of mycobacterium tuberculosis infection. Mucosal Immunol. 2021;14(1):199\u2013208.","journal-title":"Mucosal Immunol"},{"key":"4978_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70615-9","author":"H Yu","year":"2020","unstructured":"Yu H, Yang A, Derrick S, Mak JYW, Liu L, Fairlie DP, et al. Artificially induced MAIT cells inhibit M. bovis BCG but not M. tuberculosis during in vivo pulmonary infection. Sci Rep. 2020. https:\/\/doi.org\/10.1038\/s41598-020-70615-9.","journal-title":"Sci Rep"},{"issue":"5","key":"4978_CR106","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.stem.2013.03.001","volume":"12","author":"H Wakao","year":"2013","unstructured":"Wakao H, Yoshikiyo K, Koshimizu U, Furukawa T, Enomoto K, Matsunaga T, et al. Expansion of functional human mucosal-associated invariant T cells via reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 2013;12(5):546\u201358.","journal-title":"Cell Stem Cell"},{"key":"4978_CR107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2001930","author":"CR Shaler","year":"2017","unstructured":"Shaler CR, Choi J, Rudak PT, Memarnejadian A, Szabo PA, Tun-Abraham ME, et al. MAIT cells launch a rapid, robust and distinct hyperinflammatory response to bacterial superantigens and quickly acquire an anergic phenotype that impedes their cognate antimicrobial function: defining a novel mechanism of superantigen-induced immunopathology and immunosuppression. PLoS Biol. 2017. https:\/\/doi.org\/10.1371\/journal.pbio.2001930.","journal-title":"PLoS Biol"},{"key":"4978_CR108","doi-asserted-by":"crossref","unstructured":"Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells (457, pg 557, 2009). Nature. 2009;457(7233).","DOI":"10.1038\/nature07833"},{"key":"4978_CR109","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-025-10273-3","author":"YM Deng","year":"2025","unstructured":"Deng YM, Wu C, Na JT, Tang J, Qin SM, Zhang ZY, et al. Prospects and limitations of NK cell adoptive therapy in clinical applications. Cancer Metastasis Rev. 2025. https:\/\/doi.org\/10.1007\/s10555-025-10273-3.","journal-title":"Cancer Metastasis Rev"},{"issue":"19","key":"4978_CR110","doi-asserted-by":"publisher","first-page":"27764","DOI":"10.18632\/oncotarget.8526","volume":"7","author":"XL Chen","year":"2016","unstructured":"Chen XL, Han JF, Chu JH, Zhang LL, Zhang JY, Chen C, et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget. 2016;7(19):27764\u201377.","journal-title":"Oncotarget"},{"issue":"9","key":"4978_CR111","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1172\/JCI129338","volume":"129","author":"JJ Hodgins","year":"2019","unstructured":"Hodgins JJ, Khan ST, Park MM, Auer RC, Ardolino M. Killers 2.0: NK cell therapies at the forefront of cancer control. J Clin Invest. 2019;129(9):3499\u2013510.","journal-title":"J Clin Invest"},{"issue":"5\u20136","key":"4978_CR112","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1054\/tube.2001.0309","volume":"81","author":"R Nirmala","year":"2001","unstructured":"Nirmala R, Narayanan PR, Mathew R, Maran M, Deivanayagam CN. Reduced NK activity in pulmonary tuberculosis patients with\/without HIV infection: identifying the defective stage and studying the effect of interleukins on NK activity. Tuberculosis. 2001;81(5\u20136):343\u201352.","journal-title":"Tuberculosis"},{"issue":"1","key":"4978_CR113","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1365-3083.2008.02116.x","volume":"68","author":"W Barcelos","year":"2008","unstructured":"Barcelos W, Sathler-Avelar R, Martins-Filho OA, Carvalho BN, Guimaraes TMPD, Miranda SS, et al. Natural killer cell subpopulations in putative resistant individuals and patients with active Mycobacterium tuberculosis infection. Scand J Immunol. 2008;68(1):92\u2013102.","journal-title":"Scand J Immunol"},{"issue":"1","key":"4978_CR114","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/cei.13565","volume":"204","author":"F Abebe","year":"2021","unstructured":"Abebe F. Immunological basis of early clearance of mycobacterium tuberculosis infection: the role of natural killer cells. Clin Exp Immunol. 2021;204(1):32\u201340.","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"4978_CR115","doi-asserted-by":"publisher","first-page":"6639","DOI":"10.4049\/jimmunol.0902587","volume":"183","author":"R Dhiman","year":"2009","unstructured":"Dhiman R, Indramohan M, Barnes PF, Nayak RC, Paidipally P, Rao LVM, Vankayalapati R. IL-22 produced by human NK cells inhibits growth of by enhancing phagolysosomal fusion. J Immunol. 2009;183(10):6639\u201345.","journal-title":"J Immunol"},{"issue":"10","key":"4978_CR116","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.4049\/jimmunol.1201964","volume":"189","author":"B Foley","year":"2012","unstructured":"Foley B, Cooley S, Verneris MR, Curtsinger J, Luo XH, Waller EK, et al. Human cytomegalovirus (CMV)-induced memory-like NKG2CNK cells are transplantable and expand in vivo in response to recipient CMV antigen. J Immunol. 2012;189(10):5082\u20138.","journal-title":"J Immunol"},{"key":"4978_CR117","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5517856","author":"JA Chore\u00f1o-Parra","year":"2021","unstructured":"Chore\u00f1o-Parra JA, Jim\u00e9nez-Alvarez LA, Maldonado-D\u00edaz ED, Cardenas G, Fern\u00e1ndez-Lopez LA, Soto-Hernandez JL, et al. Phenotype of peripheral NK cells in latent, active, and meningeal tuberculosis. J Immunol Res. 2021. https:\/\/doi.org\/10.1155\/2021\/5517856.","journal-title":"J Immunol Res"},{"key":"4978_CR118","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ado5951","author":"TJ Scriba","year":"2024","unstructured":"Scriba TJ, Maseeme M, Young C, Taylor L, Leslie AJ. Immunopathology in human tuberculosis. Sci Immunol. 2024. https:\/\/doi.org\/10.1126\/sciimmunol.ado5951.","journal-title":"Sci Immunol"},{"issue":"12","key":"4978_CR119","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/cmi.2017.88","volume":"14","author":"CH Liu","year":"2017","unstructured":"Liu CH, Liu HY, Ge BX. Innate immunity in tuberculosis: host defense vs pathogen evasion. Cell Mol Immunol. 2017;14(12):963\u201375.","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"4978_CR120","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1007\/s00018-008-8009-2","volume":"65","author":"F Granucci","year":"2008","unstructured":"Granucci F, Zanoni I, Ricciardi-Castagnoli P. Central role of dendritic cells in the regulation and deregulation of immune responses. Cell Mol Life Sci. 2008;65(11):1683\u201397.","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"4978_CR121","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/JLB.4MR0520-112R","volume":"108","author":"TS Rodrigues","year":"2020","unstructured":"Rodrigues TS, Conti BJ, Fraga-Silva TFC, Almeida F, Bonato VLD. Interplay between alveolar epithelial and dendritic cells and mycobacterium tuberculosis. J Leukoc Biol. 2020;108(4):1139\u201356.","journal-title":"J Leukoc Biol"},{"issue":"5","key":"4978_CR122","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/JLB.4A1117-448R","volume":"103","author":"V Dirix","year":"2018","unstructured":"Dirix V, Corbi\u00e8re V, Wyndham-Thomas C, Selis E, Allard S, Hites M, et al. Blood tolerogenic monocytes and low proportions of dendritic cell subpopulations are hallmarks of human tuberculosis. J Leukocyte Biol. 2018;103(5):945\u201354.","journal-title":"J Leukocyte Biol"},{"issue":"5","key":"4978_CR123","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.4049\/jimmunol.175.5.3268","volume":"175","author":"T Tian","year":"2005","unstructured":"Tian T, Woodworth J, Sk\u00f6ld M, Behar SM. In vivo depletion of CD11c cells delays the CD4 T cell response to mycobacterium tuberculosis and exacerbates the outcome of infection. J Immunol. 2005;175(5):3268\u201372.","journal-title":"J Immunol"},{"issue":"2","key":"4978_CR124","doi-asserted-by":"publisher","first-page":"635","DOI":"10.4049\/jimmunol.159.2.635","volume":"159","author":"RA Henderson","year":"1997","unstructured":"Henderson RA, Watkins SC, Flynn JAL. Activation of human dendritic cells following infection with mycobacterium tuberculosis. J Immunol. 1997;159(2):635\u201343.","journal-title":"J Immunol"},{"issue":"5","key":"4978_CR125","first-page":"1248","volume":"121","author":"K Uehira","year":"2003","unstructured":"Uehira K, Amakawa R, Ito T, Tajima K, Naitoh S, Ozaki Y, et al. Dendritic cells are decreased in blood and accumulated in granuloma in tuberculosis. J Invest Dermatol. 2003;121(5):1248.","journal-title":"J Invest Dermatol"},{"issue":"7","key":"4978_CR126","doi-asserted-by":"publisher","first-page":"E257","DOI":"10.1016\/S1470-2045(13)70585-0","volume":"15","author":"S Anguille","year":"2014","unstructured":"Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15(7):E257\u201367.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4978_CR127","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.imlet.2013.11.016","volume":"161","author":"D Ra\u00efch-Regu\u00e9","year":"2014","unstructured":"Ra\u00efch-Regu\u00e9 D, Glancy M, Thomson AW. Regulatory dendritic cell therapy: from rodents to clinical application. Immunol Lett. 2014;161(2):216\u201321.","journal-title":"Immunol Lett"},{"issue":"2","key":"4978_CR128","first-page":"505","volume":"20","author":"K Zheng","year":"2015","unstructured":"Zheng K, Tan JM, Wu WZ, Qiu YM, Zhang H, Xu TZ, et al. Adjuvant dendritic cells vaccine combined with cytokine-induced-killer cell therapy after renal cell carcinoma surgery. J Buon. 2015;20(2):505\u201313.","journal-title":"J Buon"},{"issue":"10","key":"4978_CR129","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/sj.cgt.7700961","volume":"13","author":"JA Kyte","year":"2006","unstructured":"Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M, et al. Phase I\/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 2006;13(10):905\u201318.","journal-title":"Cancer Gene Ther"},{"issue":"7","key":"4978_CR130","doi-asserted-by":"publisher","first-page":"654","DOI":"10.4161\/viru.22586","volume":"3","author":"A Mihret","year":"2012","unstructured":"Mihret A. The role of dendritic cells in mycobacterium tuberculosis infection. Virulence. 2012;3(7):654\u20139.","journal-title":"Virulence"},{"key":"4978_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.891878","author":"H Kim","year":"2022","unstructured":"Kim H, Shin SJ. Pathological and protective roles of dendritic cells in mycobacterium tuberculosis infection: interaction between host immune responses and pathogen evasion. Front Cell Infect Microbiol. 2022. https:\/\/doi.org\/10.3389\/fcimb.2022.891878.","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"4978_CR132","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DAA Vignali","year":"2008","unstructured":"Vignali DAA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523\u201332.","journal-title":"Nat Rev Immunol"},{"key":"4978_CR133","doi-asserted-by":"crossref","unstructured":"Dong S, Hiam-Galvez KJ, Mowery CT, Herold KC, Gitelman SE, Esensten JH et al. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with 1 diabetes. Jci Insight. 2021;6(18).","DOI":"10.1172\/jci.insight.147474"},{"issue":"7","key":"4978_CR134","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","volume":"75","author":"C von Spee-Mayer","year":"2016","unstructured":"von Spee-Mayer C, Siegert E, Abdirama D, Rose A, Klaus A, Alexander T, et al. Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis. 2016;75(7):1407\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4978_CR135","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41577-019-0232-6","volume":"20","author":"C Raffin","year":"2020","unstructured":"Raffin C, Vo LT, Bluestone JA. T cell-based therapies: challenges and perspectives. Nat Rev Immunol. 2020;20(3):158\u201372.","journal-title":"Nat Rev Immunol"},{"key":"4978_CR136","doi-asserted-by":"crossref","unstructured":"Chen XC, Zhou BP, Li MZ, Deng QY, Wu XQ, Le XH et al. CD4CD25FoxP3regulatory T cells suppress. Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol. 2007;123(1):50\u20139.","DOI":"10.1016\/j.clim.2006.11.009"},{"issue":"1","key":"4978_CR137","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.clim.2006.11.009","volume":"123","author":"regulatory T cells suppress","year":"2007","unstructured":"resulting in an extra, unintended reference 137","journal-title":"Clin Immunol"},{"issue":"2","key":"4978_CR138","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/eji.200838630","volume":"39","author":"N Seddiki","year":"2009","unstructured":"Seddiki N, Sasson SC, Santner-Nanan B, Munier M, van Bockel D, Ip S, et al. Proliferation of weakly suppressive regulatory CD4 T cells is associated with over-active CD4 T-cell responses in HIV-positive patients with mycobacterial immune restoration disease. Eur J Immunol. 2009;39(2):391\u2013403.","journal-title":"Eur J Immunol"},{"issue":"11","key":"4978_CR139","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.humimm.2008.07.017","volume":"69","author":"SA Joosten","year":"2008","unstructured":"Joosten SA, Ottenhoff THM. Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. Hum Immunol. 2008;69(11):760\u201370.","journal-title":"Hum Immunol"},{"issue":"5","key":"4978_CR140","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/eji.201646875","volume":"47","author":"L Dyck","year":"2017","unstructured":"Dyck L, Mills KHG. Immune checkpoints and their inhibition in cancer and infectious diseases. Eur J Immunol. 2017;47(5):765\u201379.","journal-title":"Eur J Immunol"},{"issue":"1","key":"4978_CR141","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cyto.a.23242","volume":"93a","author":"D Mushahary","year":"2018","unstructured":"Mushahary D, Spittler A, Kasper C, Weber V, Charwat V. Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytom Part A. 2018;93a(1):19\u201331.","journal-title":"Cytom Part A"},{"issue":"9","key":"4978_CR142","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1007\/s00253-018-8912-x","volume":"102","author":"V Jossen","year":"2018","unstructured":"Jossen V, van den Bos C, Eibl R, Eibl D. Manufacturing human mesenchymal stem cells at clinical scale: process and regulatory challenges. Appl Microbiol Biotechnol. 2018;102(9):3981\u201394.","journal-title":"Appl Microbiol Biotechnol"},{"key":"4978_CR143","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01037-x","author":"T Zhou","year":"2021","unstructured":"Zhou T, Yuan ZN, Weng JY, Pei DQ, Du X, He C, et al. Challenges and advances in clinical applications of mesenchymal stromal cells. J Hematol Oncol. 2021. https:\/\/doi.org\/10.1186\/s13045-021-01037-x.","journal-title":"J Hematol Oncol"},{"key":"4978_CR144","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9529465","author":"MNF Bin Hassan","year":"2020","unstructured":"Bin Hassan MNF, Yazid MD, Yunus MHM, Chowdhury SR, Lokanathan Y, Idrus RBH, et al. Large-scale expansion of human mesenchymal stem cells. Stem Cells Int. 2020. https:\/\/doi.org\/10.1155\/2020\/9529465.","journal-title":"Stem Cells Int"},{"key":"4978_CR145","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.789644","author":"SAM Imran","year":"2022","unstructured":"Imran SAM, Hamizul MHAM, Bariah AANK, Zaman WSWK, Nordin F. Regenerative medicine therapy in Malaysia: an update. Front Bioeng Biotechnol. 2022. https:\/\/doi.org\/10.3389\/fbioe.2022.789644.","journal-title":"Front Bioeng Biotechnol"},{"key":"4978_CR146","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00737","author":"PKF Damasceno","year":"2020","unstructured":"Damasceno PKF, de Santana TA, Santos GC, Orge ID, Silva DN, Albuquerque JF, et al. Genetic engineering as a strategy to improve the therapeutic efficacy of mesenchymal stem\/stromal cells in regenerative medicine. Front Cell Dev Biol. 2020. https:\/\/doi.org\/10.3389\/fcell.2020.00737.","journal-title":"Front Cell Dev Biol"},{"key":"4978_CR147","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-03139-w","author":"JY Shin","year":"2022","unstructured":"Shin JY, Kim DY, Lee J, Shin YJ, Kim YS, Lee PH. Priming mesenchymal stem cells with \u03b1-synuclein enhances neuroprotective properties through induction of autophagy in Parkinsonian models. Stem Cell Res Ther. 2022. https:\/\/doi.org\/10.1186\/s13287-022-03139-w.","journal-title":"Stem Cell Res Ther"},{"key":"4978_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2023.1129287","author":"P Weeratunga","year":"2023","unstructured":"Weeratunga P, Harman RM, van de Walle GR. Induced pluripotent stem cells from domesticated ruminants and their potential for enhancing livestock production. Front Vet Sci. 2023. https:\/\/doi.org\/10.3389\/fvets.2023.1129287.","journal-title":"Front Vet Sci"},{"key":"4978_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.716907","author":"J Zhang","year":"2021","unstructured":"Zhang J, Chen MZ, Liao JQ, Chang CF, Liu YQ, Padhiar AA, et al. Induced pluripotent stem cell-derived mesenchymal stem cells hold lower heterogeneity and great promise in biological research and clinical applications. Front Cell Dev Biol. 2021. https:\/\/doi.org\/10.3389\/fcell.2021.716907.","journal-title":"Front Cell Dev Biol"},{"key":"4978_CR150","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-025-04315-4","author":"M Rossello-Gelabert","year":"2025","unstructured":"Rossello-Gelabert M, Igartua M, Santos-Vizcaino E, Hernandez RM. Fine-tuning licensing strategies to boost MSC-based immunomodulatory secretome. Stem Cell Res Ther. 2025. https:\/\/doi.org\/10.1186\/s13287-025-04315-4.","journal-title":"Stem Cell Res Ther"},{"key":"4978_CR151","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3390\/ijms22189676","volume":"22","author":"M Hefazi","year":"2021","unstructured":"Hefazi M, Bolivar-Wagers S, Blazar BR. Regulatory T cell therapy of graft-versus-host disease: advances and challenges. Int J Mol Sci. 2021;22:18.","journal-title":"Int J Mol Sci"},{"key":"4978_CR152","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","volume":"16","author":"S Tyagarajan","year":"2020","unstructured":"Tyagarajan S, Spencer T, Smith J. Optimizing CAR-T cell manufacturing processes during pivotal clinical trials. Mol Ther-Meth Clin D. 2020;16:136\u201344.","journal-title":"Mol Ther-Meth Clin D"},{"issue":"4","key":"4978_CR153","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/jgh.16872","volume":"40","author":"SK Shin","year":"2025","unstructured":"Shin SK, Mishima Y, Lee Y, Kwon OS, Kim JH, Kim YS, et al. Current landscape of adoptive cell therapy and challenge to develop off-the-shelf therapy for hepatocellular carcinoma. J Gastroenterol Hepatol. 2025;40(4):791\u2013807.","journal-title":"J Gastroenterol Hepatol"},{"key":"4978_CR154","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00854-y","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022. https:\/\/doi.org\/10.1186\/s12964-022-00854-y.","journal-title":"Cell Commun Signal"},{"issue":"8","key":"4978_CR155","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41565-023-01378-3","volume":"18","author":"XH Chen","year":"2023","unstructured":"Chen XH, Wang S, Chen YX, Xin HH, Zhang SS, Wu D, et al. Non-invasive activation of intratumoural gene editing for improved adoptive T-cell therapy in solid tumours. Nat Nanotechnol. 2023;18(8):933.","journal-title":"Nat Nanotechnol"},{"issue":"5","key":"4978_CR156","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1158\/1078-0432.CCR-22-2257","volume":"29","author":"GA Fenton","year":"2023","unstructured":"Fenton GA, Mitchell DA. Cellular cancer immunotherapy development and manufacturing in the clinic. Clin Cancer Res. 2023;29(5):843\u201357.","journal-title":"Clin Cancer Res"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-04978-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-04978-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-04978-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:02:23Z","timestamp":1777510943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-04978-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,22]]},"references-count":156,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4978"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-04978-7","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,22]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"164"}}